Amicus Therapeutics, Inc.
FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, aā¦ read more
Healthcare
Biotechnology
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$14.37
Price0.00%
$0.00
1Y
Price
Market Cap
$4.512b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+8.9%
EBITDA Margin+0.9%
Net Profit Margin+8.6%
Free Cash Flow Margin+8.9%
EBITDA Margin+0.9%
Net Profit Margin+8.6%
Free Cash Flow MarginRevenue
$634.210m
+20.1%
1y CAGR+24.6%
3y CAGR+20.4%
5y CAGREarnings
-$27.110m
+51.7%
1y CAGR+50.2%
3y CAGR+39.0%
5y CAGREPS
-$0.09
+50.0%
1y CAGR+50.8%
3y CAGR+40.9%
5y CAGRBook Value
$274.241m
$949.870m
Assets$675.629m
Liabilities$483.325m
DebtDebt to Assets
50.9%
9x
Debt to EBITDAFree Cash Flow
$29.849m
+179.7%
1y CAGR+95.3%
3y CAGR+75.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company